#None #NASDAQ #medical cannabis #IM Cannabis

IM Cannabis Corporation's Successful Compliance with Nasdaq Listing Standards

IM Cannabis Corp., known as IMC, is a medical cannabis company that operates in Israel and Germany. Recently, the company announced significant news regarding its compliance status with the Nasdaq Stock Market. On September 23, 2026, IM Cannabis received official communication from Nasdaq indicating that it had regained compliance with the minimum bid price requirement defined in Nasdaq Listing Rule 5550(a)(2).

This rule mandates that listed securities maintain a minimum bid price of $1.00 per share. This compliance decision was based on the company's ordinary shares maintaining a bid price of at least $1.00 for 18 consecutive business days, specifically from August 27 through September 22, 2026. This achievement marks a crucial milestone for IM Cannabis and addresses previous bid price concerns raised by Nasdaq.

The importance of this compliance cannot be overstated, as it directly influences investor confidence and the overall reputation of the company within the stock market. IM Cannabis's ability to meet these standards suggests a stable trajectory and may open doors for future growth opportunities. Following this announcement, the matter regarding the bid price deficiency has been officially resolved, allowing the company to focus on its core operations.

About IM Cannabis Corp

IM Cannabis Corp. has established itself as a key player in the medical cannabis sector, with its operations focused primarily in Israel and Germany. Through its German subsidiary, Adjupharm GmbH, the company is recognized for importing and distributing cannabis products to medical patients.

In light of upcoming transactions recently announced on August 17, 2026, the company anticipates retaining its operations in Israel while strategically divesting from its German markets. In Israel, IMC's operational framework includes a range of services such as medical cannabis retail pharmacies and online delivery platforms. These services ensure quality control and safe delivery of cannabis products to patients, emphasizing the company's commitment to patient care and compliance.

IM Cannabis leverages years of proprietary data and insights from patients to optimize its offerings and navigate the evolving landscape of the cannabis industry. As demand for medical cannabis continues to grow, IMC positions itself to harness these trends effectively.

Future Endeavors

Moving forward, IM Cannabis aims to build on its recent success and further expand its reach within the medical cannabis market. With its compliance status reinstated, the company is expected to enhance investor relations and may explore additional growth strategies. The management is optimistic about the potential for revitalized growth opportunities and looks forward to building stronger connections with existing and potential investors.

In conclusion, IM Cannabis Corp.’s recent compliance with Nasdaq's minimum bid price requirement marks a significant step in its ongoing journey. The company is poised to advance its mission of providing high-quality medical cannabis products to patients while ensuring robust operational practices and financial accountability. Stakeholders can look forward to future developments as IM Cannabis navigates an increasingly competitive landscape.